Phase 3 N=267 Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer
Advanced or Metastatic Gastric Cancer
Primary: Progression Free Survival(PFS) — 2.6; 1.8 month
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=32 Simulation-based Training for Flexible Cystoscopy - a Patient Transfer Randomized Trial
Education
Primary: Global Rating Scale — 13.6; 13.4 units on a scale — p=0.34
Phase 3 N=252 Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis
Peripheral Arterial Disease
Primary: Freedom From Target Lesion Revascularization (TLR) — 123; 43 # of participants free from TLR
Phase 2 N=326 Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)
Primary Insomnia
Primary: Sleep Efficiency (SE) on Night 1 and After 4 Weeks of Treatment — 74.8; 83.3; 84.8; 85.6 percentage of time in bed spent sleeping — p=<0.001
Phase 4 N=83 IVUS Guidance to Reduce Contrast in Coronary Angioplasty
Contrast Media Reaction · Acute Renal Failure
Primary: Total Volume of Iodine Contrast Used During Procedure — 64.5; 20.0 ml
Phase 2 N=172 Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type II
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), or Serious Adverse Events (SAEs), or Hypoglycemic Adverse Events (HAE) or Withdrawals Due to…
N/A N=1,832 Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer
Breast Cancer
Primary: Overall Survival — 82; 83 percentage of alive at 10 years — p=0.38
Phase 1 N=13 Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A
Hemophilia A
Primary: Maximum Plasma FVIII Activity (Cmax) — 1.147 IU/milliliter (mL)
Phase 2 N=34 A Study in Advanced Solid Tumors
Solid Tumor
Primary: Total Carboplatin Pharmacokinetics (PK): Area Under the Concentration (AUC) Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) — 129 micrograms*hour/milliliters…
Phase 2 N=70 Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype
Colorectal Neoplasms
Primary: Overall Survival (OS) Time — 6.71 Months
N/A N=50 Valproate for Mood Swings and Alcohol Use Following Head Injury
Traumatic Brain Injury (TBI) · Alcoholism
Primary: Severity of Affective Lability Based on Shortened Agitated Behavior Scale — 9.22; 9.39 units on a scale
Phase 3 N=266 OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement
Otitis Media With Effusion
Primary: Percentage of Participants Who Were Treatment Failures — 24.6; 44.8 percentage of treatment failures
Phase 1 N=20 Study of Vitamin D for Premenopausal Women at High Risk for Breast Cancer
Breast Cancer
Primary: Number of Participants That Successfully Completed the 1-year Intervention
Phase 2 N=42 Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid
Alzheimer's Disease
Primary: Change From Baseline in Aβ1-42 Cerebrospinal Fluid (CSF) Levels. — 75.3; -45.5; -86.2; -283.0 pg/mL
Phase 2 N=148 A Safety and Efficacy Study of Eltrombopag in Subjects With AML
Acute Leukaemia
Primary: Number of Participants With Any Adverse Events (AE) and Any Serious Adverse Events (SAE) as a Measure of Safety and Tolerability. — 72; 66; 24; 14 Participants